Optical genome mapping in acute myeloid leukemia: a multicenter evaluation

Area of Science:

• Genomics
• Hematology
• Medical Diagnostics

Background:

• Genomic aberrations are critical for acute myeloid leukemia (AML) diagnosis, prognosis, and management.
• Current cytogenetic methods (karyotyping, FISH, CMA) are labor-intensive, costly, and time-consuming.
• There is a need for more efficient and comprehensive genomic analysis in AML.

Purpose of the Study:

• To evaluate the performance of Optical Genome Mapping (OGM) in a real-world AML cohort.
• To compare OGM's diagnostic yield against standard cytogenetic techniques.
• To assess OGM's potential impact on clinical management and trial eligibility.

Main Methods:

• A cohort of 100 AML cases, previously characterized by standard methods, was analyzed using OGM.
• OGM's ability to detect structural variants (SVs) and copy number variants (CNVs) was assessed.
• Comparison of OGM findings with results from karyotyping, FISH, and chromosomal microarray analysis (CMA).

Main Results:

• OGM detected all clinically relevant SVs and CNVs identified by standard methods.
• OGM revealed clinically significant information in 13% of cases missed by routine testing.
• Three cases with normal karyotypes showed cryptic translocations via OGM.
• OGM findings could have altered clinical management in 4% and improved trial eligibility in 8% of cases.

Conclusions:

• OGM accurately identifies clinically relevant genomic aberrations in AML, matching standard methods.
• OGM offers superior detection capabilities, uncovering aberrations missed by conventional techniques.
• OGM streamlines the diagnostic process, reducing the need for multiple labor-intensive tests and enhancing diagnostic yield.